Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.

医学 催眠药 内科学 临床研究阶段 肿瘤科 临床终点 安慰剂 胃肠病学 耐受性 胃食管交界处 临床试验 随机对照试验 腺癌 不利影响 紫杉醇
作者
Rui-Hua Xu,Yanqiao Zhang,Hongming Pan,Jifeng Feng,Tao Zhang,Tianshu Liu,Yanru Qin,Shukui Qin,Xianli Yin,Baorui Liu,Yi Ba,Nong Yang,Pei Jye Voon,Suebpong Tanasanvimon,Chan Zhou,Wan Li Zhang,Lin Shen
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:6 (12): 1015-1024 被引量:1
标识
DOI:10.1016/s2468-1253(21)00313-7
摘要

Summary Background In the global phase 3 RAINBOW study, ramucirumab plus paclitaxel significantly improved overall survival compared with placebo plus paclitaxel in patients with advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. RAINBOW-Asia, a bridging study with similar design to RAINBOW, aimed to evaluate the efficacy and safety of ramucirumab plus paclitaxel for advanced gastric or GEJ adenocarcinoma in Asian, predominantly Chinese, patients. Methods RAINBOW-Asia was a randomised, double-blind, placebo-controlled, phase 3 trial done at 32 centres in China, Malaysia, the Philippines, and Thailand. Adult patients (≥18 years) with metastatic or locally advanced, unresectable gastric or GEJ adenocarcinoma who previously received fluoropyrimidine–platinum-based chemotherapy were randomly assigned with a centralised interactive web response system in a 2:1 ratio to receive ramucirumab 8 mg/kg or placebo intravenously on days 1 and 15 plus paclitaxel 80 mg/m2 intravenously on days 1, 8, and 15 of every 28-day cycle. Randomisation was stratified by Eastern Cooperative Oncology Group performance status and presence of peritoneal metastases. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done in the intention-to-treat population, and safety analysis included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov , NCT02898077 , and has been completed. Findings Between March 2, 2017, and June 30, 2020, 440 patients were randomly assigned to receive ramucirumab plus paclitaxel (n=294) or placebo plus paclitaxel (n=146). Median progression-free survival was 4·14 months (95% CI 3·71–4·30) in the ramucirumab plus paclitaxel group compared with 3·15 months (2·83–4·14) in the placebo plus paclitaxel group (hazard ratio [HR] 0·765, 95% CI 0·613–0·955, p=0·0184). Median overall survival was 8·71 months (95% CI 7·98–9·49) in the ramucirumab plus paclitaxel group and 7·92 months (6·31–9·10) in the placebo plus paclitaxel group (HR 0·963, 95% CI 0·771–1·203, p=0·7426). The most common grade 3 or worse treatment-emergent adverse events were decreased neutrophil count (159 [54%] of 293 patients in the ramucirumab plus paclitaxel group vs 56 [39%] of 145 in the placebo plus paclitaxel group), decreased white blood cell count (127 [43%] vs 42 [29%]), anaemia (46 [16%] vs 24 [17%]), hypertension (21 [7%] vs nine [6%]), and febrile neutropenia (18 [6%] vs one [ Interpretation These findings, along with the results from RAINBOW, support the use of ramucirumab plus paclitaxel as second-line therapy in a predominantly Chinese population with advanced gastric or GEJ adenocarcinoma. Funding Eli Lilly and Company, USA. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
踏实手套完成签到 ,获得积分10
2秒前
ashley325完成签到 ,获得积分10
5秒前
liuq发布了新的文献求助10
6秒前
但大图完成签到 ,获得积分10
12秒前
chen完成签到,获得积分10
19秒前
小明完成签到,获得积分10
25秒前
27秒前
知行合一完成签到 ,获得积分10
32秒前
崔宁宁完成签到 ,获得积分10
33秒前
陈荣完成签到 ,获得积分10
43秒前
gogogo完成签到,获得积分10
46秒前
mgqqlwq发布了新的文献求助10
1分钟前
HS完成签到,获得积分10
1分钟前
yes完成签到 ,获得积分10
1分钟前
英姑应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
BLAZe完成签到 ,获得积分10
1分钟前
岑靖仇完成签到 ,获得积分10
1分钟前
自由的亿先完成签到 ,获得积分10
1分钟前
guantlv完成签到,获得积分10
1分钟前
cyril完成签到 ,获得积分10
1分钟前
lyly完成签到,获得积分10
1分钟前
回首不再是少年完成签到,获得积分10
1分钟前
Oneplusssss完成签到 ,获得积分10
1分钟前
willam完成签到 ,获得积分10
2分钟前
倩倩完成签到,获得积分10
2分钟前
zzn完成签到 ,获得积分10
2分钟前
科研狗完成签到 ,获得积分10
2分钟前
wangeil007完成签到,获得积分10
2分钟前
wqc2060完成签到,获得积分10
3分钟前
赵焱峥完成签到 ,获得积分10
3分钟前
fay1987完成签到,获得积分10
3分钟前
onlooker完成签到 ,获得积分10
3分钟前
小马甲应助mgqqlwq采纳,获得10
3分钟前
ttt完成签到 ,获得积分10
3分钟前
乘风破浪完成签到 ,获得积分10
3分钟前
nicolaslcq完成签到,获得积分10
4分钟前
卡卡完成签到 ,获得积分10
4分钟前
4分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546110
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600244
捐赠科研通 1896399
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557